May 2015

Positive Preclinical Study Results Support Advancement of Amphivena’s Proprietary Bispecific CD33/CD3-Targeting Therapeutic Candidate into Clinical Development for Treatment of Acute Myeloid Leukemia (AML)  SAN FRANCISCO, CA, May 26, 2015 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced that the company will present data...